The activity of rifabutin against Mycobacterium leprae in armadillos

International Journal of Antimicrobial Agents

Volumn 9, Issue 3, 1998, Pages 169-173

  Dhople, Arvind M ^a   Williams, Sharon L ^a  

^a FLORIDA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFABUTIN; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARMADILLO; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; FOOT PAD; IN VITRO STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM LEPRAE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031950785     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00048-4     Document Type: Article

References (34)

1. Bullock WE. Rifampicin in the treatment of leprosy. Rev Infect Dis. 5:1983;S606-S613.
2. World Health Organization. A Guide to Leprosy Control, 2nd ed. Geneva: World Health Organization, 1988.
3. Sanfillipo A, Della Bruna C, Marsilli L. et al. Biological activity of a new class of rifamycins, spiropiperidyl rifamycins. J Antibiot. 33:1980;1193-1198.
4. Woodley CL, Kilburn JO. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiropiperidyl ansamycin. Am Rev Resp Dis. 126:1982;586-587.
5. Della Bruna C, Schioppacassi G, Ungheri D, Jabes D, Morvillo E, Sanfillipo A. LM427, a new spiropiperidyl rifamycin:in vitro and in vivo studies. J Antibiot. 36:1983;1502-1506.
6. Cynamon MH. Comparative in vitro activities of MDL473, rifampin and ansamycin against Mycobacterium intracellulare. Antimicrob Agent Chemother. 28:1985;440-441.
7. Heifets LB, Iseman MD, Lindholm-Levy PJ, Kanes W. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agent Chemother. 28:1985;570-575.
8. Truffot-Pernot C, Giroir AM, Grosset J. A study of the minimal inhibitory concentrations of rifabutin (ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium avium-intracellulare and Mycobacterium xenopi. Rev Mal Resp. 5:1988;401-406.
9. Hastings RC, Jacobson RR. Activity of ansamycin against Mycobacterium leprae in mice. Lancet. 2:1983;1079-1080.
10. Hastings RC, Richard VR, Jacobson RR. Ansamycin activity against rifampicin-resistant Mycobacterium leprae. Lancet. 1:1984;1130.
11. Dhople AM, Ortega I. An in vitro culture method for screening new drugs against Mycobacterium leprae. Indian J Lepr. 62:1990;66-75.
12. Dhople AM, Ibanez MA, Gardner GD. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae. Arzneim-Forsch/Drug Res. 43:1993;384-386.
13. Dhople AM, Ibanez MA. In vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae. J Antomicrob Chemother. 35:1995;463-471.
14. Dhople AM, Ibanez MA. In vitro activity of levofloxacin, singly or in combination with rifamycin analog, against Mycobacterium leprae. Antimicrob Agent Chemother. 39:1995;2116-2119.
15. Dhople AM, Dimova V. In vitro activity of a new rifamycin derivative against Mycobacterium leprae. Arzneim-Forschung/Drug Res. 46:1996;210-212.
16. Dhople AM, Ibanez MA. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Arzneim-Forsch/Drug Res. 44:1994;563-565.
17. Dhople AM, Ibanez MA. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae. Indian J Lepr. 67:1995;375-382.
18. Kirchheimer WF, Storrs EE. Attempts to establish the armadillo (Dasypus novemcinctus) as a model for the study of leprosy. Int J Leprosy. 39:1971;693-702.
19. Kirchheimer WF, Storrs EE. Leprosy in experimentally infected armadillos. Int J Lepr. 40:1972;212-213.
20. Dhople AM. Armadillo as a model for studying chemotherapy of leprosy. Indian J Lepr. 58:1986;19-28.
21. World Health Organization. Purification of Mycobacterium leprae. Proceedings of the Fifth meeting of the Scientific Working Group on the Immunology of Leprosy. Document no. TDR/IMMLEP-SWG (5) 80.3, Geneva: World Health Organization, 1980.
22. Hanks JH, Chatterjee BR, Lechat MF. A guide to the counting of mycobacteria in clinical and experimental materials. Int J Lepr. 32:1964;156-167.
23. Dhople AM, Green KJ, Osborne LJ. Limited in vitro multiplication of Mycobacterium leprae. Ann Inst Pasteur/Microbiol. 139:1988;213-223.
24. Dhople AM, Lamoureux LC. Factors influencing the in vitro growth of Mycobacterium leprae; effect of sulfhydryl compounds. Microbiol Immunol. 35:1991;209-213.
25. Dhople AM, Lamoureux LC. Factors influencing in vitro growth of Mycobacterium leprae; effect of oxygen. Microbiol Immunol. 35:1991;507-514.
26. Shepard CC. The experimental disease that follows the injection of human leprosy bacilli into footpads of mice. J Exp Med. 112:1960;445-454.
27. Skinner MH, Hsieh M, Torseth J et al. Pharmacokinetics of rifabutin. Antimicrob Agent Chemother. 33:1989;1237-1241.
28. Dhople AM. Adenosine triphosphate content of Mycobacterium lepraefrom leprosy patients. Int J Lepr. 52:1984;183-188.
29. Seydel U, Lindner B, Dhople AM. Results from cations and mass fingerprint analysis of single cells and from ATP measurements of Mycobacterium leprae. Int J Lepr. 53:1985;365-372.
30. Katoch VM. Application of bioluminescent technology to patient care and research in leprosy. Indian J Lepr. 61:1989;313-322.
31. Dietz M, Hass M, Lindner B, Dhople AM, Tebebe YB, Seydel U. Intrabacterial sodium-to-potassium ratios and ATP contents of Mycobacterium leprae from ofloxacin-treated patients. Int J Lepr. 59:1991;548-557.
32. Dhople AM, Hanks JH. In vitro growth of Mycobacterium lepraemurium, an obligate intracellulare microbe. Science. 197:1977;379-381.
33. 3H]thymidine to determine drug sensitivity of Mycobacterium leprae. IRCS J Med Sci. 14:1986;807-808.
34. Beckers B, Lang HRM, Schimke D, Lammers A. Evaluation of a bioluminescence assay for rapid antimicrobial susceptibility testing of mycobacteria. Eur J Clin Microbiol. 4:1985;556-561.